Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 12/20 | 0.53 |
| ▸ | CCND1 | P24385 | 8/20 | 0.53 |
| ▸ | CCND2 | P30279 | 8/20 | 0.53 |
| ▸ | CCND3 | P30281 | 8/20 | 0.53 |
| ▸ | AURKA | O14965 | 4/20 | 0.53 |
| ▸ | CDK1 | P06493 | 3/20 | 0.53 |
| ▸ | INSR | P06213 | 1/20 | 0.53 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.53 |
| ▸ | SRC | P12931 | 1/20 | 0.53 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.53 |
| ▸ | FLT1 | P17948 | 1/20 | 0.53 |
| ▸ | FLT4 | P35916 | 1/20 | 0.53 |
| ▸ | KDR | P35968 | 1/20 | 0.53 |
| ▸ | CDK7 | P50613 | 1/20 | 0.53 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.53 |
| ▸ | FGFR4 | P22455 | 4/20 | 0.52 |
| ▸ | CCNE2 | O96020 | 3/20 | 0.52 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.52 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.52 |
| ▸ | CDK2 | P24941 | 3/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL343541 | 1.00 | CDK4 (0.53) | CDK4CCND1CCND2CCND3AURKA | |
| SCHEMBL343365 | 0.93 | MERTK (0.53) | CDK4CCND1CCND2CCND3AURKA | |
| SCHEMBL343364 | 0.93 | MERTK (0.53) | CDK4CCND1CCND2CCND3AURKA | |
| SCHEMBL343460 | 0.90 | CDK4 (0.62) | CDK4CCND1CCND2CCND3AURKA | |
| SCHEMBL343809 | 0.86 | CDK4 (0.51) | CDK4CCND1CCND2CCND3AURKA | |
| SCHEMBL343810 | 0.84 | CDK4 (0.49) | CDK4CCND1CCND2CCND3AURKA | |
| SCHEMBL343643 | 0.82 | CDK4 (0.47) | CDK4CCND1CCND2CCND3AURKA | |
| SCHEMBL343642 | 0.82 | CDK4 (0.47) | CDK4CCND1CCND2CCND3AURKA | |
| SCHEMBL342530 | 0.82 | CDK4 (0.47) | CDK4CCND1CCND2CCND3AURKA | |
| SCHEMBL1355464 | 0.82 | CDK4 (0.57) | CDK4CCND1CCND2CCND3AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8637529-B2 | Pyrazolo[3,4-d]pyrimidine compounds | AbbYie Inc. (US) | 2014-01-28 | — | — | US | claimed |
| US-20120015963-A1 | NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS | ABBOTT LABORATORIES (US) | 2012-01-19 | — | — | US | claimed |
| US-8637529-B2 | Pyrazolo[3,4-d]pyrimidine compounds | AbbYie Inc. (US) | 2014-01-28 | — | — | US | disclosed |
| US-8637529-B2 | Pyrazolo[3,4-d]pyrimidine compounds | AbbYie Inc. (US) | 2014-01-28 | — | — | US | disclosed |
| US-8637529-B2 | Pyrazolo[3,4-d]pyrimidine compounds | AbbYie Inc. (US) | 2014-01-28 | — | — | US | disclosed |
| US-20120015963-A1 | NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS | ABBOTT LABORATORIES (US) | 2012-01-19 | — | — | US | disclosed |
| US-20120015963-A1 | NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS | ABBOTT LABORATORIES (US) | 2012-01-19 | — | — | US | disclosed |
| US-20120015963-A1 | NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS | ABBOTT LABORATORIES (US) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015963-A1 | NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS | CHUK, MAP2K2, CDK3 | CDK4 71/4885CCND1 272/4885CCND2 308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.